Abstract

FORMULATION DESIGN AND EVALUATION OF MOUTH DISSOLVING TABLETS OF DEFLAZACORT BY USING SUPERDISINTEGRANTS

Yadav Kumar Suresh*, Niranjan SK, Jain SK, Maurya Sateesh, Kumar Vinay

ABSTRACT

The present investigation of research is oriented through increasing safety and efficacy of existing drug molecule through novel concept of oral drug delivery Deflazacort is a synthetic steroid that has an antiinflammatory effect. It is used to decrease inflammation in various different diseases and conditions. Deflazacort works by acting within cells to prevent the release of certain chemicals that are important in the immune system. These chemicals are normally involved in producing immune and allergic responses; resulting in inflammation. By decreasing the release of these chemicals in a particular area, inflammation is reduced. This can help control a wide number of disease states characterized by excessive inflammation. These include severe allergic reactions, inflammation of the lungs in asthma and inflammation of the joints in arthritis. Deflazacort also decreases the numbers of white blood cells circulating in the blood. And patients Nephritic Syndrome, required steroids for long times. Mouth dissolving tablets of Deflazacort were prepared by Superdisintegrant addition method using Kyron T 314, PolyKoVidone XL, SSG, and Croscarmellose sodium as superdisintegrants at 5-10% w/w, showed minimum time to disintegrate the tablet (20.13 sec.) and almost complete release of drug within 15 minutes. The prepared 12 batches were evaluated for organoleptic properties, hardness, friability, weight variation, in vitro dispersion time, wetting time, in vitro drug release studies, in vivo and stability studies. The drug-excipients interaction was checked and found negative through IR. Finally it was concluded that Mouth dissolving tablets of Deflazacort can be successfully formulated by Superdisintegrant addition methods with improved patient compliance.

Keywords: Mouth dissolving tablets, Deflazacort, Superdisintegrants Sodium starch glycolate, Croscarmellose sodium, Kyron T-314, and PolyKoVidone XL, Direct compression method.